Drugs / GX-I7
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04283695 | Jul → Aug 2019 | leukopenia | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT06344715 | Oct 2022 → Oct 2024 | castration-resistant prostate carcinoma | SL VAXiGEN | Unknown | No outcome recorded |
| Phase 1 | NCT04730427 | Mar 2021 → May 2022 | COVID-19 | Genexine, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03733587 | Oct 2018 → Apr 2020 | cancer | Genexine, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03619239 | Jun 2018 → Sep 2020 | glioblastoma | Genexine, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03144934 | Feb 2017 → Mar 2018 | human papilloma virus infection | Genexine, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02860715 | Jul 2016 → Jan 2017 | — | Genexine, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04065087 | Aug 2019 → May 2022 | glioblastoma | Genexine, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03752723 | Mar 2019 → May 2023 | triple-negative breast carcinoma | Genexine, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05280457 | Apr 2022 → Jan 2027 expected | head and neck squamous cell carcinoma | Yonsei University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05286060 | Mar 2022 → Oct 2026 expected | head and neck squamous cell carcinoma | Yonsei University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05191784 | Jan 2022 → Dec 2024 | glioblastoma | Genexine, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04810637 | Nov 2020 → Jun 2021 | COVID-19 | PT Kalbe Genexine Biologics | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03206138 | May 2017 → Oct 2018 | cervical intraepithelial neoplasia grade 2/3 | Seoul St. Mary's Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT04289155 Background | — | glioblastoma, melanoma | Genexine, Inc. | No longer available | No outcome recorded |
Press releases naming this drug 7 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GX-I7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05280457 ↗ |
| Known as | [14C] GX-I7 | “GX-I7 or [14C] GX-I7” NCT04283695 ↗ |
| Modality | Protein / enzyme biologic | “GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc).” NCT02860715 ↗ |
| Route | Subcutaneous | “administered a single dose of GX-I7 solution for subcutaneous injection” NCT02860715 ↗ |